ABOUT THE PRODUCT
A first-in-class small molecule endothelin antagonist in a sustained-release intravitreal implant designed to improve retinal blood flow and prevent the death of retinal cells caused by the upregulation of endogenous endothelin.
Information is owner-confirmed
Last updated 1 month ago
Price range